These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2184961)

  • 21. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
    Spinas GA; Bock A; Keller U
    Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
    Lamberts SW; Oosterom R; Neufeld M; del Pozo E
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical use of the long acting somatostatin analogue octreotide in pediatrics.
    Tauber MT; Harris AG; Rochiccioli P
    Eur J Pediatr; 1994 May; 153(5):304-10. PubMed ID: 8033916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth hormone treatment of short Chinese children with beta-thalassaemia major without GH deficiency.
    Low LC; Kwan EY; Lim YJ; Lee AC; Tam CF; Lam KS
    Clin Endocrinol (Oxf); 1995 Apr; 42(4):359-63. PubMed ID: 7750189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of somatostatin analogue SMS 201-995 in normal man.
    Davies RR; Miller M; Turner SJ; Goodship TH; Cook DB; Watson M; McGill A; Orskov H; Alberti KG; Johnston DG
    Clin Endocrinol (Oxf); 1986 Jun; 24(6):665-74. PubMed ID: 2878747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Near normalization of adolescent height with growth hormone therapy in very short children without growth hormone deficiency.
    Lesage C; Walker J; Landier F; Chatelain P; Chaussain JL; Bougnères PF
    J Pediatr; 1991 Jul; 119(1 Pt 1):29-34. PubMed ID: 2066855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study.
    Shumak SL; Grossman LD; Chew E; Kozousek V; George SR; Singer W; Harris AG; Zinman B
    Clin Invest Med; 1990 Oct; 13(5):287-92. PubMed ID: 2276223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995.
    Williams G; Ball JA; Burrin JM; Joplin GF; Bloom SR
    Lancet; 1986 Oct; 2(8510):774-8. PubMed ID: 2876235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies in constitutionally tall adolescents: somatostatin decrease associated with growth hormone increase after TRH injection.
    Garcia Blanco M; Evain Brion D
    Clin Endocrinol (Oxf); 1984 Oct; 21(4):459-63. PubMed ID: 6150770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent hyperinsulinaemic hypoglycaemia of infancy: long-term treatment with the somatostatin analogue Sandostatin.
    Glaser B; Landau H; Smilovici A; Nesher R
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):71-80. PubMed ID: 2688998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children.
    Brain CE; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1990 Feb; 32(2):153-63. PubMed ID: 2140733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Final height data, body composition and glucose metabolism in growth hormone-treated short children born small for gestational age.
    Hokken-Koelega AC; van Pareren Y; Sas T; Arends N
    Horm Res; 2003; 60 Suppl 3():113-4. PubMed ID: 14671407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of SMS 201-995 on intermediary metabolism and endocrine status in normal and diabetic humans.
    Johnston DG; Davies RR; Alberti KG; Miller M; Turner SJ; Watson M; Orskov H
    Am J Med; 1986 Dec; 81(6B):88-93. PubMed ID: 2879452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995).
    Sandler LM; Burrin JM; Williams G; Joplin GF; Carr DH; Bloom SR
    Clin Endocrinol (Oxf); 1987 Jan; 26(1):85-95. PubMed ID: 2879656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults.
    Laursen T; Jørgensen JO; Christiansen JS
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):337-43. PubMed ID: 7525120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
    Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P
    J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.
    Pihoker C; Badger TM; Reynolds GA; Bowers CY
    J Endocrinol; 1997 Oct; 155(1):79-86. PubMed ID: 9390009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term management of acromegaly with sandostatin.
    Tolis G
    Horm Res; 1988; 29(2-3):112-4. PubMed ID: 2900189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.